



DEC 3 1 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

AF 1660

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Alexandria VA 22313 on

December 22,2003 HUESCHEN AND SAGE

Michel M. Dated: December 22, 2002

PF 103 PCT US

Applicant

Daniel REDOULES, Roger TARROUX, Didier FOURNIER, and

Jean-Jacques PERIE

Serial No.

09/937,673

Filed

September 28, 2001

Title

Bioprecursors of a Retinoic Derivative and Pharmaceutical

and/or Cosmetic Compositions

Art Unit

1623

Examiner

Devesh KHARE, Esq.

Honorable Commissioner for Patents Alexandria, VA 22313

RESPONSE AFTER FINAL UNDER 37 CFR § 1.111

Sir:

Responsive to the Office Action, a Final Rejection, dated October 21, 2003, the applicants comment as follows:

REMARKS

The applicants acknowledge the Examiner's Final Rejection with appreciation. Claims 16-22 and 24-33 remain under consideration. The Office maintains its rejection of Claims 16-22 and 24-30 and rejects Claims 31-33 for Obviousness under 35 USC § 103(a) based on <u>Bollag, et al.</u> (U.S. Patent No. 4,565,863) in view of <u>von Deesen, et al.</u> (U.S. Patent No. 5,126,500).

In the Response to Arguments, the Office states that "applicant has not demonstrated any criticality or unexpected result, which stems from selection of